TAK - Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript
Takeda Pharmaceutical Company Limited (TAK) Q2 2022 Results Conference Call October 28, 2021 05:30 AM ET Company Participants Christopher O’Reilly - Global Head, IR & Global Finance Christophe Weber - President and CEO Andy Plump - President Research and Development Costa Saroukos - CFO Masato Iwasaki - Japan General Affairs Ramona Sequeira - President, U.S. Business Unit and Global Portfolio Commercialization Julie Kim - President, Plasma-Derived Therapies Business Unit Conference Call Participants Hidemaru Yamaguchi - Citi Kazuaki Hashiguchi - Daiwa Securities Akinori Ueda - Goldman Sachs Steve Barker - Jefferies Seiji Wakao - JP Morgan Fumiyoshi Sakai - Credit Suisse Shinichiro Muraoka - Morgan Stanley Presentation Christopher O’Reilly Before starting, I’d like to remind everyone that we’ll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results
For further details see:
Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q2 2022 Results - Earnings Call Transcript